ARS Pharmaceuticals, Inc. (SPRY) Operating income 2020–2025
ARS Pharmaceuticals, Inc. (SPRY) annual operating income history from SEC filings — each fiscal year as reported.
-$179.4MFY2025 · since FY2020: -$32.9M → -$179.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$179.4M | -5720.6% |
| FY2024 | -$3.1M | +95.4% |
| FY2023 | -$67.5M | -90.1% |
| FY2022 | -$35.5M | -82.6% |
| FY2021 | -$19.5M | +40.9% |
| FY2020 | -$32.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice